Ihr neues Infoportal.

Sacituzumab Govitecan – Adverse Event Management

Onkologie

Zusammenfassung der ASCENT Studie

Onkologie

Sacituzumab Govitecan (SG) – Mechanism of Action

Onkologie

Sacituzumab Govitecan (SG) in Triple Negative Breast Cancers

Onkologie

Hurvitz et al.: Sacituzumab Govitecan Efficacy in Patients with Metastatic Triple-Negative Breast Cancer by HER2 Immunohistochemistry Status: Findings from the Phase 3 ASCENT Study

03.-05.05.2022 / ESMO BC 2022

Onkologie

Carey et al.: Assessment of Sacituzumab Govitecan in Black Patients From the Phase 3 ASCENT Study in Metastatic Triple‑Negative Breast Cancer

07.-10.12.2021 / ASCO 2021

Onkologie

Cortes et al.: Post-Progression Therapy Outcomes in Patients From the Phase 3 ASCENT Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

07.-10.12.2021 / SABCS 2021

Onkologie

Loibl et al.: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)

07.-10.12.2021 / SABCS 2021

Onkologie

Loibl et al.: Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

16.-21.09.2021 / ESMO 2021

Onkologie

O´Shaughnessey et al.: Analysis of Patients Without an Initial Triple-Negative Breast Cancer Diagnosis in the Phase 3 ASCENT Study of Sacituzumab Govitecan in Metastatic TNBC

16.-21.09.2020 / ESMO 2021

Onkologie

PODCAST! Von Fall zu Fall – Behandlung des Mammakarzinoms Folge 3

Vielgehört: Von Fall zu Fall – Mammakarzinom

Onkologie

PODCAST! Von Fall zu Fall – Behandlung des Mammakarzinoms Folge 2

Vielgehört: Von Fall zu Fall – Mammakarzinom

Onkologie

PODCAST! ASCO Update 2022 – Fokus Mammakarzinom

Vielgehört: Update Mammakarzinom Vol. 2

Onkologie